Intravesical liposomal tacrolimus for hemorrhagic cystitis: a phase 2a multicenter dose-escalation study.

Int Urol Nephrol · 2024 · PMC10776496 · PMID 37725274

Europe PMC DOI

hedged sentence

0.2600

closest p · 5.2× alpha

0.2600

boldest claim

The sentences

showed a trendp = 0.26not close (p > 0.1)

Thus, the 4 mg dose showed a trend towards a significant improvement over the 2 mg dose group ( p = 0.26), and the 8 mg dose group showed a statistically significant improvement over the 2 mg dose group ( p = 0.20).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.